secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2023-12-07T23:59:59+00:00
Accession:  0001193125-23-290707
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio appoints Dr. Corinne Epperly to Board, adopts amended bylaws
-------------------------------------------------------------------

- Board expanded to 8 directors; Dr. Epperly appointed as Class II director effective Dec 6, 2023, term through 2026 annual meeting.
- Dr. Epperly to serve on Compensation and Science & Technology Committees; former COO of Cargo Therapeutics and SVP at Iovance.
- Bylaws amended to comply with universal proxy rules (Rule 14a-19), enhance stockholder nominee disclosures, and adopt DGCL updates.
- Non-employee director compensation policy updated Dec 5, 2023: annual cash retainer $40k, initial option grant 54,800 shares, annual grant 27,400 shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523290707/0001193125-23-290707-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523290707/d634027d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-290707

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer